Salute e Benessere

Optometry Equipment Market is expected to generate a revenue of USD 4.54 Billion…

The Optometry Equipment Market is experiencing robust expansion due to the increasing global prevalence of vision impairment and a rise in routine eye examinations driven by awareness campaigns and better healthcare access. The Optometry Equipment Market is experiencing robust expansion due to the increasing global prevalence of vision impairment and a rise in routine eye examinations driven by awareness campaigns and better healthcare access. Key Highlights of the Report : Why This...
PR Newswire
06/05/2025

Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to…

MT PLEASANT, S.C., May 6, 2025 /PRNewswire/ -- Paradigm Therapeutics, Inc., a biopharmaceutical company, announces a $12.5 Million investment by Eshelman Ventures, LLC and appointment of Dr. Eshelman as a strategic advisor for Paradigm. SD-101 (Zorblisa™) is being developed as a topical whole-body treatment for all subtypes of Epidermolysis Bullosa (EB) patients. Funds will be used to complete all activities to support an NDA submission in the later part of 2025. MT PLEASANT, S.C. , May...
PR Newswire
06/05/2025

Continuous Positive Airway Pressure (CPAP) Devices Market to Garner $2.62…

Request a free sample copy or view report summary: Continuous Positive Airway Pressure Devices Market Request a free sample copy or view report summary:Continuous Positive Airway Pressure Devices Market The rising preference for home-based healthcare solutions and remote monitoring capabilities boosts market growth. As healthcare systems shift care delivery from hospitals to patients' homes, there is a growing interest in leveraging sleep apnea devices for home-based noninvasive...
PR Newswire
06/05/2025

Clario Announces Completion of Acquisition of WCG's eCOA Business

The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes: The addition of WCG's eCOA capabilities further amplifies Clario's leadership position in providing support for neuroscience drug development, which includes: "This acquisition is a game-changer for clinical research in neuroscience," saidTerry Burke, executive vice president and general manager of Clario's eCOA business…
PR Newswire
06/05/2025

Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare is quickly evolving into a digital-first operation, where top executives in the sector are doubling down on artificial intelligence, automation and analytics to reduce costs and improve billing accuracy. This is according to results of a survey from Everest Group (and supported by Omega Healthcare), which showed 85% of senior healthcare executives believe AI will improve efficiencies over the next five years. Now that multitasking AI Agents…
PR Newswire
06/05/2025

Vistin Pharma ASA (VISTN): Mandatory notification of trade and disclosure of…

Ferncliff Listed Dai AS has on 6 May 2025 sold 1,234,280 shares in Vistin Pharma ASA at NOK 22.50 per share.Saga Pure ASA has on 6 May 2025 sold 700,000 shares in Vistin Pharma ASA at NOK 22.50 per share.After the transaction Saga Pure ASA and Ferncliff Listed Dai AS has no holding of shares in Vistin Pharma ASA. Øystein Stray Spetalen and associated parties have a holding of 331,886 shares in Vistin Pharma ASA.Saga Pure ASA and Ferncliff Listed Dai AS are closely associated with board...
Nasdaq GlobeNewswire
06/05/2025

Boehringer Ingelheim starts Phase II study of its potential first-in-class oral…

Ingelheim, Germany, May 6, 2025– Boehringer Ingelheim today announces the start of the JADE Phase II clinical study (NCT06769048), investigating the efficacy and safety of BI 1584862 as a potential first-in-class treatment for geographic atrophy (GA). [1] Geographic atrophy (GA) is an eye disease that can lead to irreversible vision loss. [2]It affects more than five million people worldwide, of which more than 40% are considered blind, ...
Nasdaq GlobeNewswire
06/05/2025

Niall Prendiville Joins CSafe as Chief Product Officer to Drive Continued Growth…

Niall is a global product and engineering leader with deep expertise in engineering, automation, and supply chain operations. He has successfully led product development, engineering, and business transformations across high-tech industries, including warehouse automation, power systems, and aerospace. As the Chief Product Officer at CSafe, he will drive innovation, product strategy, and commercialization to support the company's long-term success across CSafe's robust portfolio of active and…
PR Newswire
06/05/2025

Global Survey from World Lupus Federation Finds Nearly Half of People with Lupus…

Lupus nephritis occurs when the immune system mistakenly attacks the kidneys, leading to inflammation and possibly to long-term organ damage, including kidney failure, if left untreated. Although most cases of lupus nephritis begin within five years of a lupus diagnosis, nearly one in five survey respondents who self-report having symptoms of kidney involvement have not been told by a doctor they have lupus nephritis. Lupus nephritis occurs when the immune system mistakenly attacks the…
PR Newswire
06/05/2025

"Gedeon Richter House of Hope" opens its doors to support 300 women annually in…

The "Gedeon Richter House of Hope" was implemented by the Hungary-based Close to Africa Foundation in cooperation with its local partner, the Sini Sanuman Foundation. Richter covered a substantial portion of the construction costs and will also support the operation for at least the next 4 years. Part of the equipment expenses were covered by the Hungary Helps Program, an initiative of the Hungarian Government. The center was designed by a team of Hungarian architects who also ensured…
PR Newswire
06/05/2025

IM Cannabis to Report First Quarter 2025 Financial Results on Thursday, May 15th…

The Company will host a zoom web conference on the same day at9:00am ETto discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clickinghere. All relevant information will be sent upon registration. If you are unable to join us live, a recording of the call will be available on our website athttps://investors.imcannabis.comwithin 24 hours after the call. Link for the zoom call:https://us02web...
PR Newswire
06/05/2025

Safe Life Enters Swiss Market with Acquisition of resQshock

"We are excited to bring resQshock on board to the Safe Life group," says Jimmy Eriksson, CEO of Safe Life. "Their strong market position, experienced team, and fantastic customer relationships mirror Safe Life's foundations and positions. By adding a leading position in Switzerland, we take yet another important step toward our mission of making life-saving technology more accessible across Europe." "We are excited to bring resQshock on board to the Safe Life…
PR Newswire
06/05/2025

EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025

EnteroBiotix Presents Positive IBS-C Data at Digestive Disease Week® 2025EBX-102-02 was well tolerated and demonstrated clinically meaningful improvements across multiple symptom domains in IBS-C patientsPh2b trial in IBS-C initiating in H2 2025 to confirm efficacyGlasgow, Scotland – 6 May 2025.EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today presented positive data from its TrIuMPH Phase 2a trial...
Nasdaq GlobeNewswire
06/05/2025

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of…

Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.TSPO-PET imaging showed significant reductions in microglial activation at six months (p<0.05). NEW YORK, May06, 2025(GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing...
Nasdaq GlobeNewswire
06/05/2025

Cryogenic Valve Assembly Market worth $7.21 billion by 2029 | MarketsandMarkets™

159 - Tables74 - Figures179 – Pages 159 - Tables 74 - Figures 179 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=225850120 The Valve Body, by Component The valve body segment accounts for a significant share of the Cryogenic Valve Assembly Market due to its importance in withstanding low temperatures and high pressures. The demand for stronger and more reliable materials in LNG, industrial gas, and aerospace applications drives the...
PR Newswire
06/05/2025

Waters Integrates Multi-Angle Light Scattering Detectors with Empower Software…

Empower Software is the industry's most established and compliant-ready chromatography data system (CDS), widely adopted globally and used to submit data for more than 80% of novel drugs to regulatory authorities.4 The new integration unlocks the ability to use MALS techniques in quality control for biotherapeutics, improving efficiency and Good Manufacturing Practices (GMP) readiness, while reducing end-user training in compliant settings. Empower Software is the industry's most established...
PR Newswire
06/05/2025

Wobble Genomics Announces Appointment of Dr. Dietrich A. Stephan as Chairman of…

Dr. Stephan is a notable figure in the biotechnology industry, with a career distinguished by leading many major genomics efforts and founding and leading multiple successful biotech ventures. His expertise is in molecular diagnostics, therapeutic development, and genome interpretation. Dr. Stephan played a leading role in ushering in the era of personalised genetic medicine in both germline disease and oncology. In germline disease, as co-founder of Navigenics, the first direct-to-consumer…
PR Newswire
06/05/2025

NTG Nordic Transport Group A/S - Q1 2025 Conference Call

NTG Nordic Transport Group A/S – Q1 2025 Conference Call We expect to release the Q1 2025 results of NTG Nordic Transport Group in the evening of May 12, 2025. A webcast and conference call will be held in the morning of May 13, 2025, at 10:00 am CET. At the call, Group CEO Mathias Jensen-Vinstrup and Group CFO Christian D. Jakobsen will present the Q1 2025 Interim Financial Report. The presentation will be followed by a Q&A session.Date:May 13, 2025Time:10:00 am CET To...
Nasdaq GlobeNewswire
06/05/2025

Leo Cancer Care France and Centre Léon Bérard Awarded Prestigious FEDER Grant to…

The awarded project will focus on validating and optimising the use of Leo Cancer Care's upright proton therapy solution, Marie®, in a clinical setting, to enhance treatment efficiency, improve patient comfort, and enable greater accessibility to proton therapy. The aim of the 'Proton Radiotherapy Centre' project is to offer this therapeutic arsenal to patients in the AURA region. The awardedprojectwill focus on validating and optimising the use ofLeo Cancer Care'supright proton therapy...
PR Newswire
06/05/2025

Astraveus Enters Strategic Partnership with NecstGen to evaluate Lakhesys…

Astraveus recently demonstrated the potential of its revolutionary Lakhesys Benchtop Cell Factory™ with the first ever, end-to-end production of CAR-T cells within a microfluidic benchtop system and is now starting external testing of its new manufacturing platform. Astraveus' technology, and its unique microfluidic approach, possesses the ability to simultaneously decrease manufacturing costs as well as increase process efficiency and throughput many times over. Astraveus recently…
PR Newswire
06/05/2025

TFS HealthScience Expands Collaboration with Oncomatryx for Phase Ib Trial of…

This Phase Ib study builds on an earlier collaboration between TFS and Oncomatryx during a Phase I trial evaluating OMTX705 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. The promising results from that study laid the foundation for this next phase of development and exemplified the consistent performance, deep therapeutic expertise, and oncology specialization that Oncomatryx values in its continued partnership with TFS. This Phase Ib study...
PR Newswire
06/05/2025

Essential Pharma strengthens management team with appointment of Duncan Ferguson…

Egham, UK – 6th May 2025– Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients in niche populations, today announces the appointment of Duncan Ferguson as Vice President, Commercial.Duncan joins Essential today and will support the continued growth of the Company's portfolio of medicines for small, underserved or rare disease populations. He will join the Leadership Team and drive the commercial strategy of the...
Nasdaq GlobeNewswire
06/05/2025

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production…

Exercised options total USD 143.6 millionSecures manufacturing and supply of freeze-dried JYNNEOS ®to the U.S. in 2026COPENHAGEN, Denmark, May 6, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 million under the existing...
Nasdaq GlobeNewswire
06/05/2025

Lundbeck joins forces with Danish Centre for AI Innovation to improve brain…

Lundbeck expects that Gefion will contribute to advancing research by providing AI-driven insights into molecule discovery and drug optimization in the development of therapies. By exploring innovative avenues for molecule discovery, Lundbeck aims to identify novel and better medicines for known drug targets as well as unlocking emerging drug targets to deliver new treatment options for people living with brain disorders, including rare and specialist-treated neurological conditions. Lundbeck...
PR Newswire
06/05/2025
Altri  Comunicati